MARALIXIBAT CHLORIDE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated in alagille syndrome and pruritus and has 2 investigational indications. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Lopixibat chloride and Livmarli. Its PubChem CID is 9831642.
Maralixibat chloride
| CAS No | 228113-66-4 |
|---|---|
| Molecular Formula | C40H56ClN3O4S |
| Molecular Weight | 710.40 g/mol |
| Synonyms | (4R,5R)-5-[4-[[4-(4-aza-1-azoniabicyclo[2.2.2]octan-1-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2H-1λ6-benzothiepin-4-ol chloride |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
MARALIXIBAT CHLORIDE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated in alagille syndrome and pruritus and has 2 investigational indications.
The listed CAS number is 228113-66-4.
The listed molecular formula is C40H56ClN3O4S.
The listed molecular weight is 710.40 g/mol.
(4R,5R)-5-[4-[[4-(4-aza-1-azoniabicyclo[2.2.2]octan-1-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2H-1λ6-benzothiepin-4-ol chloride.
The source lists Lopixibat chloride and Livmarli.